Practical strategies for switching to newer antiepileptic drugs

Reviews in Neurological Diseases

Volumn 2, Issue 4, 2005, Pages 186-198

  Kuzniecky, Ruben I ^a   Mortati, Katherine ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Add on therapy; Antiepileptic drugs; Epilepsy; Lennox Gastaut syndrome; Seizure control

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; ETHINYLESTRADIOL; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LITHIUM; METFORMIN; MORPHINE; NAPROXEN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RISPERIDONE; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

ANHIDROSIS; ANOREXIA; ARTHRITIS; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EPILEPSY; FOCAL EPILEPSY; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPONATREMIA; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LANGUAGE DISABILITY; LENNOX GASTAUT SYNDROME; LIVER FAILURE; LIVER TOXICITY; METABOLIC ACIDOSIS; NEPHROLITHIASIS; OPEN ANGLE GLAUCOMA; PARESTHESIA; PERIPHERAL EDEMA; PHOTOSENSITIVITY DISORDER; RASH; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STUPOR; TIC; TOXIC EPIDERMAL NECROLYSIS; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; CHILD; CLINICAL TRIALS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE;

EID: 29744450149     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Centers for Disease Control and Prevention. Epilepsy. Available at: http://www.cdc.gov/epilepsy. Accessed June 9, 2005.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
3. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
4. Casetta I, Granieri E, Desiderá M, et al. Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology. 1997;16:296-303.
5. Nordli DR Jr. Special needs of the adolescent with epilepsy. Epilepsia. 2001;42(suppl 8):10-17.
6. Biton V. Effect of antiepileptic drugs on body-weight: overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003;17:781-791.
7. Linde J, Hansen JM, Siersbæk-Nielsen K, Fuglsang-Fredriksen V. Bone density in patients receiving long-term anticonvulsant therapy. Acta Neurol Scand. 1971;47:650-651.
8. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127:256-262.
9. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 2003;44(suppl 4):21-29.
10. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383-1388.
11. Tegretol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.
12. RxList.com. Phenobarbital-warnings and precautions. Available at: http://www.rxlist.com/cgi/generic3/phenbarb_wcp.htm. Accessed June 9, 2005.
13. Phenytoin oral suspension USP [package insert]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; 2003.
14. Depakote ER [package insert]. North Chicago, IL: Abbott Laboratories; 2004.
15. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40:601-607.
16. Nieto-Barrera M, Brozmanova M, Capovilla G, et al, on behalf of the Lamictal vs Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res. 2001;46:145-155.
17. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.
18. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-213.
19. Chadwick DW, Anhut H, Greiner MJ, et al, and the International Gabapentin Monotherapy Study Group 945-77. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 1998;51:1282-1288.
20. Privitera MD, Brodie MJ, Mattson RH, et al, for the EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-175.
21. Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res. 2002;S2:61-69.
22. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75-79.
23. Morris GE, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav. 2004;5:509-512.
24. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51:1018-1025.
25. Brodie MJ, Overstall PW, Giorgi L. Multicenter, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res. 1999;37(1):81-87.
26. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476-479.
27. Albani F, Grassi B, Ferrara R, et al, and the PRIMO Study Group. Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure. 2004;13:254-263.
28. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3:70-76.
29. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451-460.
30. Isojärvi JIT, Pakarinen AJ, Rautio A, et al. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia. 1994;35:1217-1220.
31. Isojärvi JIT, Airaksinen KEJ, Mustonen JN, et al. Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine. Epilepsia. 1995;36:810-816.
32. Guerrini R, Carpay J, Groselj J, et al, on behalf of the TOP-INT-51 Investigators' Group. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure. 2005;14:371-380.
33. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure. 2000;9:137-141.
34. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52:1882-1887.
35. Neurontin [package insert]. New York, NY: Parke-Davis; 2004.
36. Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004.
37. Keppra [package insert]. Smyrna, GA: UCB Pharma, Inc.; 2004.
38. Trileptal [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
39. Gabitril [package insert]. West Chester, PA: Cephalin, Inc.; 2005.
40. Topamax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2004.
41. Zonegran [package insert]. Teaneck, NJ: Eisai Inc.; 2004.
42. Smith PEM, for the UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure. 2001;10:87-91.
43. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-87.
44. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252-1260.
45. Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs. 2001;15:609-621.
46. Cantero J, Weintraub D, Buchsbaum R, Hirsch L. Cosmetic side effects of the antiepileptic drugs. Presented at: 58th Annual Meeting of the American Epilepsy Society; December 3-8, 2004; New Orleans, LA.
47. Faught E, Ayala R, Montouris GG, Leppik IE, and the Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774-1779.
48. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45:1330-1337.
49. Sveinbjornsdottir S, Sander JWAS, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure. 1994;3:29-35.
50. Dodrill CB, Arnett JL, Somerville KW, Shu V. Cognitive and quality of life effects of differing doses of tiagabine in epilepsy. Neurology. 1997;48:1025-1031.
51. Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry. 1997;62:372-376.
52. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia. 1999;40:1279-1285.
53. Neyens LGJ, Alpherts WCJ, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:411-419.
54. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000;41:1167-1178.
55. Thompson PJ, Baxendale SA, Duncan JS, Sander JWAS. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636-641.
56. Weatherly G, Carlson BE, Risse GL, et al. Cognitive test performance of patients taking zonisamide (ZNS) [abstract]. Epilepsia. 2003;44(suppl 9):127. Abstract 1.36S.
57. Aldenkamp AP, Arends J, Bootsma HPR, et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia. 2002;43:19-26.
58. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and lamotrigine [abstract]. Neurology. 2000;54(suppl 3):A84. Abstract S16.003.
59. Schachter SC. Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia. 1999;40(suppl 9):S20-S25.
60. Cunnington M, Tennis P, and the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64:955-960.
61. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med. 2004;71(suppl 2):S25-S37.
62. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003;4:310-317.
63. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy, clinical experience in Argentina. Epilepsy Behav. 2004;5:163-167.
64. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia. 1996;37:1242-1244.
65. ten Berg K, Samrén EB, van Oppen AC, et al. Levetiracetam use and pregnancy outcome. Reprod Toxicol. 2005;20:175-178.
66. Leppik IE, Gram L, Deaton R, Somerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res. 1999;33:23S-246.
67. Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia. 2001;42:764-771.
68. Mervaala E, Koivisto K, Hänninen T, et al. Electiophysiological and neuropsychological profits of lamotrigine in young and age-associated memory impairment (AMMI) subjects [abstract]. Neurology. 1995;45(suppl 4):A259. Abstract 357P.
69. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs. 2004;18:617-628.